From Pilots to Production: Healthcare's Agentic Turn in 2026

Field view
2026

In April 2026, Merck signed a partnership with Google Cloud worth up to $1 billion, embedding an "agentic" AI platform across its research, manufacturing, and commercial operations. Days earlier, Novo Nordisk had struck a company-wide agreement with OpenAI; and at January's J.P. Morgan Healthcare Conference, Eli Lilly and NVIDIA had committed up to $1 billion over five years to a co-innovation lab, extending what is already the pharmaceutical industry's most powerful AI supercomputer. Read together, the headlines suggest an industry sprinting confidently into an AI-defined future.

The view from inside those companies is more complicated — and more useful. In a widely cited ZoomRx survey, 83% of pharma professionals described AI as "overrated" — a blunt verdict on years of pilots that dazzled in demos and stalled in production. Both things are true at once, and the tension between them is the real story of healthcare AI in 2026.

The industry has reached what analysts have started calling the agentic pivot: the point at which the question shifts from whether AI works to whether it can be scaled into disciplined, measurable operations. Getting across that line, it turns out, has less to do with the model than with everything around it.

78%

AI adoption
in digital health

What "agentic" changes

The distinction driving the moment is technical but consequential. Where earlier tools answered questions or drafted text, an AI agent — in BCG's phrasing — can observe, plan, and act, carrying a multi-step task across the systems involved and pausing for a human at the decisions that matter. Google Cloud's Shweta Maniar frames the trajectory as a move "from R&D to R&P" — research to prediction — with systems that reason through noisy data to nominate drug candidates in months rather than years.

Adoption reflects the enthusiasm. NVIDIA's State of AI in Healthcare and Life Sciences: 2026 Trends, published in February, found AI adoption rising across every segment — 78% in digital health, 74% in medtech — with agentic AI, a first-time entry, already cited by 47% of respondents as in use or under assessment. Eighty-five percent expected their AI budgets to grow this year. Analysts at GlobalData put healthcare AI spending north of $100 billion in 2026.

The pilot-to-
production gap

The scaling wall

Then comes the hard part. Scaling is the thesis of the year's conference agendas, themed around industrializing intelligence. The scene is familiar to anyone in the field: an operations team staring at a pilot that worked, trying to explain to leadership why the next step costs three times as much.

The disillusionment is real and, arguably, healthy. BCG warns against the most common failure pattern — a sprawl of dozens of disconnected pilots — and finds that successful organizations instead concentrate on a small number of opportunities with genuinely transformative potential.

75%

reduction in time
to actionable insight

Where agents are actually working

Strip away the noise and a consistent pattern emerges: agents earn their keep first on work that is high-volume, well-defined, and documented — slow and repetitive for people, easy for a system to check.

In discovery, that means replacing brute-force screening of thousands of compounds with models that reason toward the most promising candidates; BCG expects agentic AI to compress parts of drug development from years to months, and Lilly's new supercomputer is aimed squarely at accelerating molecular hypothesis testing. In data operations, agentic "orchestrators" now ingest and clean clinical data across incompatible sources, with BioPharm International reporting up to a 75% reduction in the time needed to reach actionable insight.

The commercial side is moving too. IQVIA — which finds that consistent launch excellence across multiple markets is achieved in fewer than one in ten launches, a measure of how genuinely hard the task is — describes agentic planning that compresses prelaunch analytics, and conversational field agents that cut administrative friction for sales and medical teams; territory alignment, on some accounts, collapses from weeks to minutes. And the least glamorous work may matter most: the most visible near-term impact is likely to come from logistics and administration — scheduling, documentation, coding, utilization management, and care coordination — the connective tissue of care delivery.

Human-in-the-loop
by design

Trust is the moat

In regulated care, none of this scales without trust — and trust is engineered, not assumed. Roughly 80% of firms now run formal AI governance committees, a sharp turn toward oversight after the pilot era. The regulatory landscape has gained, in BioPharm International's words, unprecedented clarity — albeit with higher compliance bars, with scrutiny scaled to a model's influence on decisions and its consequences for patients.

The practical translation is human-in-the-loop by design. In IQVIA's account of what actually works, three lessons recur: technology alone delivers nothing without change management; not every problem needs an agent; and human–AI collaboration should augment expert judgment, not replace it, with people reviewing and approving agent actions — especially early on. That supervision is what builds the organizational confidence to scale.

BCG's rule of thumb
for programs that
reach production

The seventy percent that isn't the model

Perhaps the most quoted rule of the year is BCG's "10-20-70": successful AI efforts spend 10% of their energy on algorithms, 20% on technology and data, and fully 70% on people and process. The model is the easy part. Change management is the work.

$100B+

healthcare AI
spending in 2026

The companies moving fastest apply a simple discipline: first identify the high-volume, high-value processes where speed or precision moves revenue or cost; then decide which specific tasks can be scoped, measured, and handed to an agent — and which stay with a human. The question shifts from "will AI replace my team?" to "which jobs should agents own, and which shouldn't?" Because agentic AI is only as good as what it sees, the unglamorous work of fixing data foundations quietly decides who succeeds. The organizations seeing impact embed AI into existing workflows instead of layering it on top as a separate tool.

The takeaway

Beyond the billion-dollar headlines, the evidence from 2026 tells a consistent story: the winners won't be the companies with the flashiest models or the largest GPU clusters, but the ones that pick the right work, keep humans accountable, fix their data, and treat change as the main event rather than an afterthought. The reward is both prosaic and profound — handing scarce clinical and scientific time back to the people who do the work. The pivot is underway. The advantage goes to the disciplined.